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Abstract 
Background. Postoperative outcomes of patients with advanced heart failure undergoing ventricular assist device 
implantation are strongly influenced by their preoperative Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS) profiles. We sought to investigate whether a similar association exists in patients 
undergoing emergency heart transplantation.  
Methods and Results. By means of the Spanish National Heart Transplant Registry database, we identified 704 adult 
patients treated with emergency heart transplantation in 15 Spanish centers between 2000 and 2009. Post-transplant 
outcomes were analyzed pertaining to patient preoperative INTERMACS profiles, which were retrospectively 
assigned by 2 blinded cardiologists. Before transplantation, INTERMACS profile 1 (critical cardiogenic shock) was 
present in 207 patients, INTERMACS profile 2 (progressive decline) in 291, INTERMACS profile 3 (inotropic 
dependence) in 176, and INTERMACS profile 4 (resting symptoms) was present in 30 patients. In-hospital 
postoperative mortality rates were, respectively, 43%, 26.8%, and 18% in patients with profiles 1, 2, and 3 to 4 
(P<0.001). INTERMACS 1 patients also presented the highest incidence of primary graft failure (1: 31.3%, 2: 22.3%, 
3–4: 21.8%; P=0.03) and postoperative need for dialysis (1: 33.2%, 2: 18.9%, 3–4: 21.5%; P<0.001). Adjusted odds-
ratios for in-hospital postoperative mortality were 4.38 (95% confidence interval, 2.51–7.66) for profile 1 versus 3 to 
4, 2.49 (95% confidence interval, 1.56–3.97) for profile 1 versus 2, and 1.76 (95% confidence interval, 1.02–3.03) for 
profile 2 versus 3 to 4. Long-term survival after hospital discharge was not influenced by preoperative INTERMACS 
profiles.  
Conclusions. Preoperative INTERMACS profiles determine outcomes after emergency heart transplantation. Results 
call for a change in policies related to the management of heart transplant candidates presenting with INTERMACS 
profiles 1 and 2.  
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Introduction 
Emergency heart transplantation (HT) is the choice therapeutic option for selected critically ill patients 
with heart failure (HF) with a nonreversible underlying cardiac disease and an imminent risk of death.1,2 
A careful candidate evaluation is warranted to optimize postoperative outcomes, which have been 
reported to be worse than after elective HT procedures.3 In the current era of increasing scarcity of donors 
and waiting list times,3 the need for accurate clinical tools to assess the perioperative risk of emergency 
HT candidates is even more evident. Unfortunately, scoring scales validated for outcome prediction 
during HF hospitalizations4,5 have limited reliability in critically ill patients, as this population has not 
been sufficiently represented in validation studies.  
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles of 
advanced HF were defined in the setting of a multi-institutional registry of ventricular assist devices 
(VADs) to clarify the clinical characterization of HF patients with a failed response to conventional 
treatment. The aims were to facilitate communication among colleagues and to improve risk stratification 
and selection of target populations for advanced therapies.6 Until now, 4 small single-center studies have 
investigated the association between INTERMACS profiles and outcomes in the field of advanced HF: 3 
focused on patients undergoing VAD implantation7–9 and 1 focused on patients undergoing emergency 
HT.10 All studies showed worse postoperative outcomes in patients with a more critical preoperative 
clinical condition, as is the case of individuals with INTERMACS profiles 1 and 2. The purpose of our 
investigation was to analyze postoperative outcomes in the Spanish national cohort of emergency HT 
patients, and to correlate them with preoperative INTERMACS profiles. 
Methods 
Setting, Design, Patients, and Data Collection 
In Spain, the procurement and distribution of organ donors is coordinated by the Organización Nacional 
de Trasplantes (ONT), a public healthcare network that integrates all hospitals with capability for organ 
extraction or implantation around the country. In the past decade, an HT candidate could be listed in the 
ONT system with 2 different levels of priorities: emergent (the so-called ONT status 0) or elective. ONT 
status 0 implied priority over all elective HT candidates for receiving the first suitable donor heart 
available in the system. In that era, ONT status 0 was reserved for critically ill HF patients who met ≥1 of 
the following criteria:  
 
 Dependence on an intra-aortic balloon pump (IABP), a short-term VAD, or an extracorporeal 
membrane oxygenator (ECMO). 
 Dependence on both intravenous inotropes and invasive mechanical ventilation with orotracheal 
intubation. 
 Recurrent life-threatening ventricular arrhythmias despite optimal pharmacological and device 
therapy. 
 Nonreversible primary graft dysfunction during the early postoperative period after a first HT. 
 
We performed an observational study based on the historical cohort of patients aged >18 years who 
underwent emergency HT (ONT status 0) in Spain between 2000 and 2009. Patients were identified by 
means of the prospective database of the Spanish National Heart Transplant Registry (SNHTR),3 in which 
extensive clinical information on recipients, donors, and outcomes is recorded about all HT procedures 
performed in our country since the first was carried out in May 8, 1984. This database is updated on a 
yearly basis with data reported voluntarily by all Spanish HT teams.  
A formal research proposal was presented to the head of every 1 of the 16 Spanish teams that had 
performed any adult HT procedure in the past decade. All teams except 1 approved the protocol. 
Therefore, we extracted from the SNHTR database a data set of 175 clinical variables related to ONT 
status 0 HT procedures performed between January 1, 2000, and December 31, 2009, at the 15 centers 
participating in the study, which are listed in the Acknowledgments section. A data set of other 37 
additional clinical variables was collected directly from patient hospital clinical records, which were 
individually reviewed for the study. Two cardiologists blinded to post-transplant outcomes retrospectively 
judged the clinical status of every patient just at the time of HT surgery and assigned them a preoperative 
INTERMACS profile as previously defined6 (Table 1). Reliable information about the vital status of all 
patients was available as of October 31, 2010. Other major post-transplant outcomes were defined as 
follows:  
 
 Primary graft failure: left ventricular or biventricular systolic dysfunction of the graft, as 
assessed by visual inspection in the operating room or defined by the finding of a left ventricular 
ejection fraction <45% by transthoracic or transesophageal echocardiography during the first 48 
hours after surgery, in the absence of rejection or other obvious causes of graft dysfunction, 
causing severe hemodynamic instability (systolic blood pressure <90 mm Hg and cardiac index 
<2.2 mL/min per m2), and requiring high-dose intravenous inotropes (dopamine or dobutamine 
>10 μg/kg per min), intravenous vasopressors (norepinephrine or epinephrine >0.1 μg/kg per 
min) or mechanical circulatory support (MCS) with IABP, short-term VADs or ECMO.  
 Isolated right ventricular failure: isolated right ventricular systolic dysfunction of the graft, as 
assessed by visual inspection in the operating room or defined by transthoracic or 
transesophageal echocardiography performed during the first 48 hours after surgery as the 
presence of a lateral tricuspid annulus plane systolic excursion <15 mm or a right ventricular 
ejection fraction <45% together with normal or near-normal left ventricular systolic 
performance, in the absence of other obvious causes of graft dysfunction, causing severe 
hemodynamic instability (systolic blood pressure <90 mm Hg and cardiac index <2.2 mL/min 
per m2), and requiring high-dose intravenous inotropes (dopamine or dobutamine >10 μg/kg per 
min), intravenous vasopressors (norepinephrine or epinephrine >0.1 μg/kg per min) or MCS with 
IABP, short-term VADs or ECMO.  
 Major bleeding: surgical bleeding requiring transfusion of >4 red cell units at the operation room 
or within the first 48 hours after surgery, requiring intravenous vasopressor agents 
(norepinephrine or epinephrine >0.1 μg/kg per min) because of persistent hypotension (systolic 
blood pressure <90 mm Hg), or leading to cardiac reoperation with repeated sternotomy during 
the postoperative hospitalization after HT.  
 Cardiac reoperation: any cardiac surgical procedure requiring a new sternotomy during the 
postoperative hospitalization after HT.  
 Dialysis: need for dialysis or hemofiltration during the postoperative hospitalization after HT. 
 Infection: any episode of culture-proven infection or empirical treatment for suspected infection 
during the postoperative hospitalization after HT. Asymptomatic cytomegalovirus infection was 
not considered an infectious event.  
Table 1. INTERMACS Profiles of Advanced Heart Failure6 
Profiles Definition Description 
   
INTERMACS 
1 
Critical cardiogenic 
shock (Crash and 
burn) 
Patient with life-threatening hypotension despite rapidly escalating inotropic support, 
critical organ hypoperfusion, often confirmed by worsening acidosis and lactate levels.  
INTERMACS 
2 
Progressive decline 
(Sliding fast on 
inotropes) 
Patient with declining function despite intravenous inotropic support, that may be manifest 
by worsening renal function, nutritional depletion, or inability to restore volume balance. 
Also describes declining status in patients unable to tolerate inotropic therapy.  
INTERMACS 
3 
Stable but inotrope 
dependent 
(Dependent 
stability) 
Patient with stable blood pressure, organ function, nutrition, and symptoms on continuous 
intravenous inotropic support (or a temporary circulatory support device or both), but 
demonstrating repeated failure to wean from support because of recurrent symptomatic 
hypotension or renal dysfunction.  
INTERMACS 
4 
Resting symptoms 
on oral therapy at 
home 
Patient can be stabilized close to normal volume status but experiences daily symptoms of 
congestion at rest or during activities of daily living. Doses of diuretics generally fluctuate 
at very high levels. More intensive management and surveillance strategies should be 
considered, which may in some cases reveal poor compliance that would compromise 
outcomes with any therapy. Some patients may shuttle between 4 and 5.  
INTERMACS 
5 
Exertion intolerant 
Comfortable at rest and with activities of daily living but unable to engage in any other 
activity, living predominantly within the house. Patients are comfortable at rest without 
congestive symptoms, but may have underlying refractory elevated volume status, often 
with renal dysfunction. If underlying nutritional status and organ function are marginal, 
patient may be more at risk than INTERMACS 4, and require definitive intervention.  
INTERMACS 
6 
Exertion limited 
(Walking wounded) 
Patient without evidence of fluid overload is comfortable at rest, and with activities of 
daily living and minor activities outside the home but has fatigue after the first few 
minutes of any meaningful activity. Attribution to cardiac limitation requires careful 
measurement of peak oxygen consumption, in some cases with hemodynamic monitoring 
to confirm severity of cardiac impairment.  
INTERMACS 
7 
Advanced NYHA 
class III 
(Placeholder) 
A placeholder for more precise specification in future. This level includes patients who are 
without current or recent episodes of unstable fluid balance, living comfortably with 
meaningful activity limited to mild physical exertion.  
   
 
INTERMACS indicates Interagency Registry for Mechanically Assisted Circulatory Support; and NYHA, New York Heart 
Association. 
Statistical Analysis 
Continuous variables are presented as mean±SD, and categorical variables are presented as proportions. 
χ2 Tests and ANOVA were used for statistical comparisons among groups, and Scheffé test was used for 
post hoc pairwise comparisons.  
A multivariable logistic regression model was built to estimate the adjusted odds ratio for in-hospital 
postoperative mortality after HT across INTERMACS profiles. Variables included in the analysis were 
those considered as potential confounders on the basis of previous publications, clinical experience, or a 
marked asymmetrical distribution among INTERMACS groups (age, sex, donor age, donor sex, ischemic 
heart disease, diabetes mellitus, preoperative infection, dialysis, mechanical ventilation, VAD, cold 
ischemia time, previous cardiac surgery, second HT, donor on inotropes, and year of transplantation).  
Post-transplant long-term survival curves of patients with preoperative INTERMACS profiles 1, 2, 
and 3 to 4 were estimated by means of the Kaplan–Meier method and compared by means of the log-rank 
test, both in the entire cohort and in the subcohort of patients who survived the in-hospital postoperative 
period and were discharged alive. Adjusted hazard ratios for all-cause death and all-cause death 
conditioned to hospital discharge were obtained by means of multivariable Cox proportional hazards 
models. Statistical significance was set as a P value <0.05. All analyses were performed with SPSS 
Statistics version 20.  
Results 
Recipients, Donors, and Heart Transplant Procedures 
According to the SNHTR database, 2956 patients aged >18 years underwent HT in our country between 
2000 and 2009. Seven hundred and twenty-four patients underwent emergency (ONT status 0) HT; 711 of 
them at the 15 hospitals participating in the study. Seven patients were excluded because hospital clinical 
records lacked enough clinical information to make a reliable judgment about their preoperative 
INTERMACS profile. Therefore, the final study sample included 704 patients.  
At the time of HT, 207 patients (29.4%) had an INTERMACS profile 1, 291 (41.3%) an 
INTERMACS profile 2, 176 (25%) an INTERMACS profile 3, and 30 patients (4.3%) had an 
INTERMACS profile 4. No patient presented with INTERMACS profiles 5 to 7. Figure 1 shows the 
distribution of patients during the study period. For subsequent analyses, patients with INTERMACS 
profiles 3 and 4 were included in a single category.  
 
 
 
 
Figure 1. Distribution of patients during the study period. INTERMACS indicates Interagency Registry for Mechanically Assisted 
Circulatory Support.  
As shown in Table 2, the mean age was 48.6 years in the INTERMACS 1 group, 51.6 years in the 
INTERMACS 2 group, and 50.4 years in the INTERMACS 3 to 4 group (P=0.020). The proportion of 
women was ≈20% in the 3 groups. While awaiting HT, INTERMACS 3 to 4 group patients were 
supported with lower doses of inotropes, as measured by means of the inotropic index,11 and less 
frequently needed mechanical ventilation, intra-aortic balloon pumping, or temporary MCS as a bridge to 
HT in comparison with patients with INTERMACS profiles 1 and 2. 
Table 2. Clinical Variables Related to Recipients, Donors, and Heart Transplant Procedures 
Variables 
INTERMACS 1 
(n=207) 
INTERMACS 2 
(n=291) 
INTERMACS 3–4 
(n=206) 
P Value* 
 
Demographics 
Age, y; mean, SD 48.6±12.4 51.6±11.6 50.1±12.5 0.025† 
Women, % 20.3 19.6 20.4 0.97 
Waiting list time, d 4.6±6.3 5.4±7.4 5.6±6.8 0.33 
Clinical history 
Ischemic heart disease, % 43.5 48.5 46.1 0.55 
Diabetes mellitus, % 14.0 13.1 14.6 0.88 
Hypertension, % 22.7 27.8 28.2 0.35 
Previous cardiac surgery, % 23.5 27.7 23.3 0.44 
Defibrillator, % 16.1 18.8 27.7 0.009 
Resynchronization, % 7.0 6.0 7.5 0.80 
Cardiac arrest, % 23.9 17.6 17.6 0.19 
Preoperative infection, % 32.4 27.8 22.8 0.030‡ 
Supportive therapies 
Inotropes, % 95.1 97.9 85.4 <0.001‡§ 
Inotropic index 43.9±72.8 32.2±55.6 8.4±13.2 <0.001†§ 
Intra-aortic balloon, % 79.2 72.5 44.2 <0.001‡§ 
Temporary mechanical circulatory 
support, % 
18.8 18.9 6.3 <0.001‡§ 
Dialysis, % 13.5 5.9 5.5 0.003†‡ 
Mechanical ventilation, % 63.8 46.9 25.9 <0.001†‡§ 
Laboratory 
Creatinine, mg/dL 1.6±0.9 1.3±0.6 1.2±0.5 <0.001†‡ 
Creatinine clearance, mL/min per m2 70.9±33 78.1±35.4 85.8±42.1 <0.001†‡ 
Hemoglobin, g/dL 11.4±2.1 11.1±2.2 11.5±2.1 0.34 
Bilirubin, mg/dL 2.1±1.3 1.9±1.5 1.9±1.6 0.62 
Aspartate aminotransferase, IU/L 331±1005 208±622 118±328 0.020 
Alanine aminotransferase, IU/L 351±1055 252±725 159±367 0.019 
Hemodynamics 
Ejection fraction, % 20.2±10.7 21.1±9.6 21.8±10.8 0.28 
Cardiac index, mL/min per m2 2.0±0.7 2.2±0.7 2.2±0.7 0.019 
Central venous pressure, mm Hg 12.7±6.7 13.6±6.2 12.2±7.2 0.33 
Capillary wedge pressure, mm Hg 23.5±8.7 24.2±8.7 25.6±8.8 0.11 
Mean pulmonary pressure, mm Hg 32.3±10.5 33.0±10.9 35.0±11.0 0.07 
Heart transplant surgery 
Second heart transplantation, % 2.9 5.8 3.9 0.26 
Cold ischemia time, min 216.1±62.5 214.4±55.8 208.8±58.8 0.41 
Bypass time, min 146.8±70.3 130.6±44.5 133.6±52.0 0.005† 
Donor characteristics 
Female donor, % 30.7 25.5 30.0 0.39 
Donor on inotropes, % 69.3 80.8 79.5 0.014†‡ 
Donor with cardiac arrest, % 6.5 9.1 5.8 0.41 
Donor age, y 36.1±12.9 36.8±12.9 34.7±12.1 0.20 
Immunosuppressive therapy 
Induction therapy, % 70.3 86.7 83.2 <0.001 
Cyclosporine, % 66.3 54.3 62.4 0.03 
Tacrolimus, % 23.4 38.0 32.1 0.005 
Mycophenolate mofetil, % 75.3 80.1 85.8 0.034 
Azathioprine, % 21.8 12.6 11.6 0.007 
Mammalian target of rapamycin 
inhibitors, % 
7.5 3.6 4.1 0.14 
     
 
INTERMACS indicates Interagency Registry for Mechanically Assisted Circulatory Support. 
↵* Statistical pairwise comparisons:  
↵† P<0.05 for INTERMACS 1 vs INTERMACS 2.  
↵‡ P<0.05 for INTERMACS 1 vs INTERMACS 3–4.  
↵§ P<0.05 for INTERMACS 2 vs INTERMACS 3–4.  
Inotropic index is calculated as dopamine dose (μg/kg per min)+dobutamine dose (μg/kg per min)+15×milrinone dose (μg/kg per 
min)+100×epinephrine dose (μg/kg per min)+100×norepinephrine dose (μg/kg per min).11 
  
Patients with INTERMACS profile 1 had the lowest mean cardiac index and the highest mean serum 
levels of creatinine, alanine aminotransferase, and aspartate aminotransferase among the 3 studied groups. 
Preoperative need for dialysis and preoperative infection were also more frequent in INTERMACS 1 
patients.  
No significant difference among preoperative INTERMACS profiles was noticed pertaining to donor 
age, donor sex, or cold ischemia times, but a higher proportion of inotrope-supported donors were used in 
the INTERMACS 1 group. Patients with INTERMACS profile 1 also presented the longest mean bypass 
time during HT surgery.  
Early Postoperative Outcomes 
The rates of major postoperative outcomes during in-hospital follow-up after HT are shown in Figure 2. 
The incidence of primary graft failure was 31.3% among patients with INTERMACS profile 1, 
significantly higher than among patients with INTERMACS profile 2 (22.3%; P=0.03) and patients with 
INTERMACS profiles 3 to 4 (21.8%; P=0.02). The postoperative need for dialysis was also more 
frequent in the INTERMACS 1 group (33.2%) than in the INTERMACS 2 group (18.9%; P<0.001) and 
in the INTERMACS 3 to 4 (21.5%; P=0.001) group. The incidence of isolated right ventricular failure, 
major surgical bleeding, cardiac reoperation, and postoperative infection was not significantly different 
across preoperative INTERMACS profiles.  
 
 
 
Figure 2. In-hospital postoperative outcomes after emergency heart transplantation. Statistically significant post hoc pairwise 
comparisons (P value <0.05) are shown in the figure. INTERMACS indicates Interagency Registry for Mechanically Assisted 
Circulatory Support; Redo, cardiac reoperation; and RV, right ventricle.  
Survival After HT 
Mean follow-up after HT was 1174±42 days. Two hundred and ninety-six patients (42%) died: 204 
patients (29%) during in-hospital follow-up and 92 patients (13%) after hospital discharge. Primary graft 
failure, multiorgan failure, and infection were the most frequent causes of death during the early 
postoperative period, although rejection (acute and chronic), malignancy, and infection accounted for the 
majority of deaths during postdischarge long-term follow-up. Causes of deaths pertaining to preoperative 
INTERMACS profiles are detailed in Figure 3.  
 
 
 
 
Figure 3. Causes of death pertaining to preoperative Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) profiles. A, Causes of death during in-hospital postoperative follow-up. B, Causes of death during long-term 
follow-up after hospital discharge.  
In-hospital postoperative mortality after HT was 43% in the INTERMACS 1 group, 26.8% in the 
INTERMACS 2 group, and 18% in the INTERMACS 3 to 4 group (P<0.001; Figure 2). Mortality 
differences across preoperative INTERMACS profiles remained statistically significant over eras (years 
2000–2003, INTERMACS 1: 38.4%, INTERMACS 2: 20.5%, INTERMACS 3–4: 17.6%, P=0.002; years 
2004–2006, INTERMACS 1: 44.2%, INTERMACS 2: 25.3%, INTERMACS 3–4: 17.7%, P=0.002; years 
2007–2009, INTERMACS 1: 47.8%, INTERMACS 2: 33.3%, INTERMACS 3–4: 18.6%, P=0.001). 
Adjusted odds-ratios for in-hospital postoperative mortality were 4.38 (95% confidence interval [CI], 
2.51–7.66) for INTERMACS profile 1 versus 3 to 4, 2.49 (95% CI, 1.56–3.97) for INTERMACS profile 
1 versus 2 and 1.76 (95% CI, 1.02–3.03) for INTERMACS profile 2 versus 3 to 4.  
As shown in Figure 4A, post-transplant long-term survival curves were significantly different across 
preoperative INTERMACS profiles, with the best outcomes corresponding to patients with INTERMACS 
profiles 3 to 4 and the worst corresponding to patients with INTERMACS profile 1 (overall comparison, 
P<0.001; pairwise comparisons, INTERMACS 1 versus 2, P=0.010; INTERMACS 1 versus 3–4, 
P<0.001; INTERMACS 2 versus 3–4, P=0.005). Adjusted hazard ratios for all-cause death were 2.14 
(95% CI, 1.46–3.12) for INTERMACS profile 1 versus 3 to 4, 1.43 (95% CI, 1.04–1.94) for 
INTERMACS profile 1 versus 2, and 1.50 (95% CI, 1.01–2.15) for INTERMACS profile 2 versus 3 to 4.  
  
 
 
 
Figure 4. Long-term survival after heart transplantation. A, Entire cohort. B, Patients discharged alive from hospital after heart 
transplantation. INTERMACS indicates Interagency Registry for Mechanically Assisted Circulatory Support.  
Post-transplant long-term survival curves of patients who survived the early postoperative period and 
were discharged from the hospital did not vary significantly across INTERMACS groups (P<0.25; Figure 
4B). Adjusted hazard ratios for all-cause death conditioned to hospital discharge were 0.91 (95% CI, 
0.48–1.71) for INTERMACS profile 1 versus 3 to 4, 0.64 (95% CI, 0.36–1.13) for INTERMACS profile 
1 versus 2, and 1.43 (95% CI, 0.86–2.40) for INTERMACS profile 2 versus 3 to 4.  
Discussion 
The main finding of our study is the strong correlation observed between preoperative INTERMACS 
profiles and postoperative outcomes in the Spanish national cohort of patients treated with emergency HT 
between 2000 and 2009. Moreover, the poor outcomes observed in emergency HT recipients presenting 
with INTERMACS profiles 1 and 2 call for a reformulation of policies related to the management of these 
critically ill HF patients.  
Adjudication of INTERMACS profiles was fairly accurate in our study. The INTERMACS profile 1 
represented a very sick HF population presenting with impaired hemodynamics and end-organ 
dysfunction, frequently requiring high-dose intravenous inotropes and invasive supporting therapies, and 
affected by device-related complications such as infection. On the other hand, patients with 
INTERMACS profiles 3 and 4 were usually bridged to HT with a more stable hemodynamic condition 
under low-dose or even no inotropic therapy, and with relatively preserved hepatic and kidney function. 
INTERMACS profile 2 represented an intermediate situation. No patient was assigned to INTERMACS 
profiles 5 to 7, consistently with the definition of a less severe clinical scenario in which emergency HT is 
rarely justified.  
Rates of postoperative adverse events after HT as primary graft failure and renal failure were 
significantly different across INTERMACS profiles, with the best outcomes corresponding to patients 
with profiles 3 and 4, and the worst corresponding to patients with profile 1. Adjusted risk of in-hospital 
postoperative death for this population was increased by 2.5-fold relating to INTERMACS 2 patients and 
increased by 4.4-fold relating to INTERMACS 3 to 4 patients. Adjusted risk of in-hospital postoperative 
death of INTERMACS 2 patients was also increased by 1.7-fold in comparison with INTERMACS 3 to 4 
patients. However, the long-term survival of patients discharged alive after the early postoperative period 
was not affected by preoperative INTERMACS profiles, and was comparable with that reported for stable 
patients undergoing elective HT.3,12 Our results are concordant with an earlier Spanish single-center 
registry of 111 patients treated with emergency HT,10 except that no significant survival differences 
between patients with INTERMACS profiles 2 and 3 to 4 were observed in this previous study.  
Outcome differences across INTERMACS profiles were not attributable to variability in the quality of 
donors or in the length of cold ischemia times, supporting the impression that the preoperative clinical 
condition of the recipient is a strong determinant of post-transplant outcomes. The donor heart is exposed 
to a series of graded insults from brain death to cold ischemic time and subsequent ischemic-reperfusion 
injury.13 It is, therefore, necessary to assure that the milieu into which this vulnerable organ is reset is as 
physiologically stable to accept it as possible.13 Recipients with hemodynamic impairment, such as those 
with high central venous pressure or requiring inotropic support, or with comorbidities, such as advanced 
age or diabetes mellitus, are exposed to a higher risk of primary graft failure.14 This complication is 
associated with a poor prognosis15 and accounts for a significant proportion of deaths during the early 
postoperative period after HT.  
The overall in-hospital postoperative mortality in our study (29%) represents >2-fold increase in 
comparison with the Spanish historical cohort of elective HT procedures.3 These results are not 
satisfactory; although specific selection criteria may vary among teams, HT should not generally be 
considered unless post-transplant 1-year survival can be reasonably predicted to exceed 85%.16 These 
data may reflect a liberal and, even in some cases, inappropriate selection of candidates for emergency 
HT. It is possible, indeed, that some patients have been transplanted despite a poor clinical condition, 
nonreversible end-organ failure, and a low expectation to survive the operation. This reality must be 
regarded in the context of the short waiting list times, an average of 5 days in our study, which have 
historically characterized the Spanish ONT. This peculiarity of our organ donor allocation system is the 
result of a vast and well-organized network of centers provided with specifically dedicated healthcare 
professionals and organ extraction facilities nationwide, also favored by a legally regulated presumed 
donor consent of all Spanish citizens. Paradoxically, it seems that the broad and quick availability of 
donors might have made Spanish clinicians willing to accept biological replacement by means of a donor 
heart as the choice rescue therapy for the majority of patients with critical HF, even for those with rapidly 
deteriorating clinical status and a high risk of early postoperative complications after HT. Apart from 
economic conditioning, it also seems that this reality might have prevented Spanish healthcare authorities 
from feeling the necessity to develop other therapeutic options for these patients, such as MCS.  
In view of a high early postoperative mortality, listing for emergency HT should not be recommended 
for patients presenting with INTERMACS profile 1, and probably not for many patients presenting with 
INTERMACS profile 2, at least until clinical stabilization has been achieved. Although no randomized 
clinical trials have been performed to determine the optimal management of these critically ill patients, 
current practice in many centers includes early implantation of a temporary MCS device, for example, 
extracorporeal VADs or ECMO, as a first step for the further evaluation of permanent therapies, such as 
HT or durable VADs. Mechanical devices usually result in hemodynamic improvement and favor the 
recovery of end-organ function. In patients who meet the candidacy criteria for HT, the goal of MCS is 
not only to keep them alive while awaiting for an organ donor, but also to improve their clinical condition 
so as to undergo the procedure with a reasonable probability of survival. HT, indeed, should be 
contraindicated because of futility in patients who experience progressive clinical deterioration and 
develop irreversible multiorgan failure while supported on a functioning device.2 
The expected benefits of MCS should always be balanced with the potential risk of device-related 
complications,17 such as infection, thrombosis, bleeding, or immunologic sensitization.18 Several studies 
have addressed the question of whether preoperative MCS may adversely impact post-transplant 
outcomes, with controversial results.12,19,20 Notwithstanding this, outcomes of patients with profiles 1 and 
2 who underwent emergency HT in our cohort were inferior to those of patients undergoing VAD 
implantation as a bridge to HT in the INTERMACS registry.17 Moreover, in a recent single-center study, 
patients with profiles 1 and 2 who underwent VAD implantation as a bridge to HT had a significantly 
higher survival than those primarily listed for emergency HT.21 
In Spain, the use of MCS as a bridge to HT has been historically very infrequent, and almost restricted 
to temporary devices. Currently, this reality is changing, both in view of the unsatisfactory results of the 
previous strategy and also conditioned by a new scenario of increasing scarcity of donors and waiting list 
times.3 As of 2010, after the end of the present study, a new policy for donor heart allocation has been 
approved in our country. Since then, the highest waiting list priority level (ONT status 0) is reserved only 
for HT candidates supported on a temporary MCS device or for those experiencing severe complications 
of a long-term implantable VAD, such as infection, embolism, or mechanical dysfunction. In recent years, 
Spanish multicenter registries have shown a steady increase in the number of temporary MCS devices 
implanted3 and HT performed in temporarily supported candidates nationwide,22 although the 
implantation of long-term durable VADs remains as almost anecdotic. Therefore, the extension of the use 
of long-term durable VADs emerges as a major challenge for Spanish healthcare authorities in the future 
years.  
Our study has several limitations. Because of its observational, retrospective, nonrandomized design, 
information, selection and confusion biases may not be ruled out completely. Also, given the peculiarities 
of our organ procurement and allocation system, results may not be reproducible in other countries, 
therefore, external validity is not warranted. Finally, the study was not able to address several important 
questions raised about the management of critically ill HT candidates. Further investigation is warranted 
to determine which stable inotrope-dependent patients may undergo HT directly and which should 
undergo semielective implantation of a durable VAD as a bridge to HT. The complexity of the clinical 
decision-making process is even greater in patients recovering from cardiogenic shock with temporary 
MCS devices. No evidence-based recommendations may be stated about how long it is reasonable to wait 
under temporary support before listing the patient for high-emergency HT or before implanting a long-
term VAD, or how to proceed if the patient develops progressive right ventricular failure. In these cases, 
the decision between HT and long-term VAD implantation may be extremely difficult, because 
biventricular devices are associated with less favorable outcomes.17 
In conclusion, our national cohort study shows a strong correlation between preoperative 
INTERMACS profiles and postoperative outcomes after emergency HT. Even in a setting of short 
waiting list times, the post-transplant outcomes of patients with INTERMACS profiles 1 and 2 were not 
satisfactory. Further investigation is warranted to determine the role of temporary and long-term MCS as 
a way to optimize HT candidate selection and organ donor distribution.  
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